Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - yellow fever vaccine 1000 [iu] (17d strain);   - suspension for injection - 1000 iu - active: yellow fever vaccine 1000 [iu] (17d strain)   excipient: alanine calcium chloride dihydrate dibasic sodium phosphate dihydrate histidine hydrochloride lactose monohydrate magnesium sulfate heptahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sorbitol purified water sodium chloride - prevention of yellow fever. vaccination is recommended for: · every person over 9 months of age living or travelling through an endemic area. · non-vaccinated persons moving from an endemic to a potentially receptive non-endemic area. · laboratory workers handling potentially infectious materials. · in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - mycophenolate sodium 192.4mg eqv mycophenolic acid - enteric coated tablet - 192.4mg - mycophenolate sodium 192.4mg eqv mycophenolic acid 180mg

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - mycophenolate sodium 384.8mg eqv mycophenolic acid - tablet, film coated - 384.8 mg - mycophenolate sodium 384.8mg eqv mycophenolic acid 360 mg

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - canakinumab - powder, for solution - 150mg - canakinumab 150mg

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

oz crop pty ltd - picloram present as the hexyloxypropylamine salt; triclopyr present as the butoxyethyl ester - emulsifiable concentrate - picloram present as the hexyloxypropylamine salt anilide/aniline-pyrimidine active 100.0 g/l; triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 300.0 g/l - herbicide

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

pharma mar s.a. - trabectedin - ovarian neoplasms; sarcoma - antineoplastic agents - yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.yondelis in combination with pegylated liposomal doxorubicin (pld) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

echem (aust) pty limited - picloram hexyloxypropylamine salt; triclopyr butoxyethyl ester - emulsifiable concentrate - picloram hexyloxypropylamine salt anilide-aniline-pyrimidine active 100.0 g/l; triclopyr butoxyethyl ester pyridine-pyridinoxy active 300.0 g/l - herbicide

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - asunaprevir -